9th Dec 2024 19:42
GSK PLC - London-based pharmaceuticals firm - Says Dreamm-7 trial shows sustained overall survival benefit for Blenrep, the brand name of belantamab mafodotin, combination versus a daratumumab combination. The data build on findings from Dreamm-7 and Dreamm-8 and supports the potential for Blenrep combinations to become standard of care. Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse, company says. Read More
